AstraZeneca rejects Pfizer's "final" bid

Share this article:

Managers from AstraZeneca rebuffed another offer to relinquish their autonomy, saying Pfizer's latest bid for the British drugmaker, a Friday night proposal valued at 69.4 billion pounds ($117 billion), was too low. The rejection of the bid, which Pfizer said was final, left the two drugmakers in a stalemate over a deal that would have created the world's largest drugmaker.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.